 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...156157158159160161162163164165166...235236» |
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal, Combination therapy: Combination Therapy With S-1, Oxaliplatin and Leucovorin in Patients With Advanced Esophageal Squamous Cell Carcinoma. (Pubmed Central) - Mar 14, 2020
SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 13, 2020
P2, N=53, Suspended, Sponsor: Children's Oncology Group
SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC. Trial completion date: Jun 2020 --> Sep 2020 | Trial primary completion date: Jun 2020 --> Sep 2020
- | Trial completion, Trial completion date, Metastases: Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer (clinicaltrials.gov) - Mar 13, 2020
P=N/A, N=103, Completed, Sponsor: Asan Medical Center
Trial completion date: Jun 2020 --> Sep 2020 | Trial primary completion date: Jun 2020 --> Sep 2020 Recruiting --> Completed | Trial completion date: Jan 2021 --> Feb 2020
- ||| TTX-030 / AbbVie, Trishula Therap
New P1 trial, Metastases: ELTIVATE: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (clinicaltrials.gov) - Mar 12, 2020
P1, N=152, Not yet recruiting, Sponsor: Tizona Therapeutics, Inc
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Journal: Integrated care pathway for rectal cancer treatment: cross-sectional post-implementation study using a logic model framework. (Pubmed Central) - Mar 12, 2020
Recruiting --> Completed | Trial completion date: Jan 2021 --> Feb 2020 The logic model was useful for evaluating the implementation of the integrated care pathways and for identifying measurements to be made in future outcome studies.
- | New P2 trial, Metastases: Chemotherapy mFOLFIRINOX in Locally Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov) - Mar 12, 2020
P2, N=100, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | Erbitux (cetuximab) / Eli Lilly
Biomarker, Trial completion date, Trial primary completion date, Monotherapy, Metastases: Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC (clinicaltrials.gov) - Mar 11, 2020
P2/3, N=200, Not yet recruiting, Sponsor: Ruijin Hospital
The logic model was useful for evaluating the implementation of the integrated care pathways and for identifying measurements to be made in future outcome studies. Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
- | New P3 trial: Adjuvant Chemotherapy in High Risk Stage II Colon Cancer (clinicaltrials.gov) - Mar 11, 2020
P3, N=962, Not yet recruiting, Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: CALGB: Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 10, 2020
P3, N=2334, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2020 --> Oct 2021 Active, not recruiting --> Completed
- | BNT321 / BioNTech
Enrollment change, Trial completion date, Trial primary completion date: MV-0715-CP-001.01: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies (clinicaltrials.gov) - Mar 10, 2020
P1, N=108, Recruiting, Sponsor: BioNTech Research & Development, Inc.
Active, not recruiting --> Completed N=68 --> 108 | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- | Trial completion: Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma (clinicaltrials.gov) - Mar 10, 2020
P2, N=30, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
N=68 --> 108 | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Active, not recruiting --> Completed
- leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Real World Experience of FOLFIRINOX in Elderly Patients with Metastatic Pancreatic Cancer () - Mar 9, 2020 - Abstract #HOPA2020HOPA_345;
Research in progress. Results will be presented.
- leucovorin calcium / Generic mfg., Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda, Servier
Impact of Treatment Sequence on Overall Survival in Metastatic Pancreatic Cancer Patients Treated with Irinotecan Liposomal in the Real-World Setting (Screen 9) () - Mar 9, 2020 - Abstract #HOPA2020HOPA_291;
As expected, Sequence 2 patients had a longer overall survival than Sequence 1 patients. Further real-world studies are needed to understand the impact of treatment sequences on survival outcomes in nal-IRI treated patients.
- leucovorin calcium / Generic mfg.
Evaluation of Peripheral Neuropathy (PN) with Total Neoadjuvant Therapy (TNT) in Colorectal Cancer Patients (CRC) () - Mar 9, 2020 - Abstract #HOPA2020HOPA_254;
Results to be presented. Results to be discussed.
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Evaluation of Leucovorin Rescue After Mini-Dose Methotrexate for Graft-Versus-Host Disease Prophylaxis () - Mar 9, 2020 - Abstract #HOPA2020HOPA_247;
Pending data collection. Conclusions/ Pending data collection analysis.
- Determining the Safety and Efficacy of 7-7 Versus 14-7 Schedules of Capecitabine in Metastatic Colorectal Cancer (mCRC): A Retrospective Review () - Mar 9, 2020 - Abstract #HOPA2020HOPA_199;
This study was an IRB approved, retrospective, cohort study of adult patients with histologically confirmed mCRC receiving capecitabine +/- bevacizumab, panitumumab, or cetuximab in either a 14-7 or 7-7 schedule... Results will be included upon final data analysis.
- leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Atropine Use in Oncologic Patients Receiving Irinotecan-based Chemotherapy () - Mar 9, 2020 - Abstract #HOPA2020HOPA_160;
This retrospective review will give insight into practice at Nebraska Medicine and the opportunity to educate and update our practice guidelines in regards to irinotecan and atropine. This review seeks to identify adverse outcomes associated with atropine, which may support or lead to the change of Nebraska Medicine’s policy on administering atropine only in cases where patients experience cholinergic symptoms.
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Improving the Safe and Effective Use of High-Dose Methotrexate for Lymphoma Management (Ballroom BC) - Mar 9, 2020 - Abstract #HOPA2020HOPA_96;
We report the results of a prospective, observational, investigation that longitudinally evaluated Cystatin C, Urinary neutrophil gelatinase-associated lipocalin (NGAL), and tissue inhibitor metalloproteinase-2 and insulin-like growth factor binding protein 7 (TIMP2•IGFBP7) in lymphoma patients receiving MTX for treatment or prophylaxis of CNS disease. Learning Objectives: Describe the association of serum methotrexate (MTX) concentrations with clinical outcomes following MTX administration as treatment or prophylaxis of central nervous system lymphoma Illustrate the longitudinal patterns of novel renal biomarkers up to 96 hours after the administration of high-dose methotrexate (HDMTX, >1gram/m2) as a 4-hour infusion Discuss the utility of novel renal biomarkers as potential predictors of elevated serum MTX concentrations or acute kidney injury after HDMTX administration
- || napabucasin (BBI608) / Sumitomo Pharma
New P1 trial: Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols (clinicaltrials.gov) - Mar 9, 2020
P1, N=10, Enrolling by invitation, Sponsor: Boston Biomedical, Inc
- NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC) () - Mar 8, 2020 - Abstract #ENETS2020ENETS_61;
- [VIRTUAL] COST-EFFECTIVENESS ANALYSIS OF NAB-PACLITAXEL PLUS GEMCITABINE VERSUS FOLFIRINOX IN FIRST LINE TREATMENT OF METASTATIC PANCREATIC CANCER IN CHINA () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_721;
OBJECTIVES: Nab-paclitaxel Abraxane® plus gemcitabine (AG) and Fluorouracil, leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) have shown significant clinical benefit and been widely used as 1st-line treatment of metastatic pancreatic cancer (mPC) in China. As the first study comparing cost-effectiveness of these two regimens, AG is likely the better option for the 1st-line mPC treatment compared with FOLFIRINOX in China.
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
[VIRTUAL] MODEL-BASED COST-EFFECTIVENESS ANALYSES OF SYSTEMIC THERAPIES FOR METASTATIC COLORECTAL CANCER- A SYSTEMATIC METHODOLOGICAL REVIEW () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_668;
Model-based cost-effectiveness analyses of systemic mCRC treatments have adopted varied modelling methods and structures, resulting in substantially different outcomes. As models generally focus on first-line treatment without consideration of downstream treatments, there is a profound source of structural uncertainty implying that the cost-effectiveness of treatments across the mCRC pathway remains uncertain.
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
[VIRTUAL] HEALTHCARE RESOURCE UTILIZATION AND COSTS IN METASTATIC PANCREATIC CANCER- A SYSTEMATIC LITERATURE REVIEW () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_646;
mPC and mPC treatments are associated with frequent hospitalizations and emergency room visits. Furthermore, nab-P/GEM and FOLFIRINOX were associated with high administration and supportive care costs.
- [VIRTUAL] THE BUDGETARY IMPACT OF GENETIC-GUIDED DOSING OF 5-FLUOROURACIL, IRINOTECAN, LEUCOVORIN, AND BEVACIZUMAB (FOLFIRI+BEV) IN METASTATIC COLORECTAL CANCER (MCRC) () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_519;
Implementation of genetically-guided dosing for FOLFIRI+bev in patients with mCRC is cost-saving from the perspective of the health care system over a 5-year time horizon. Further work should be done to determine how to implementation, and the impact of improved outcomes due to a reduction of avoidable adverse events.
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., paclitaxel / Generic mfg.
[VIRTUAL] TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION IN FIRST-LINE THERAPY FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN ASIAN AND WESTERN COUNTRIES () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_494;
Variation by Asian and Western countries were observed for AE-related HRU but not for PS following treatment, treatment response, or outcomes. Burden of disease for these 1L patients exists regardless of geography suggesting a need for improved treatments.
- | Journal: Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. (Pubmed Central) - Mar 7, 2020
Burden of disease for these 1L patients exists regardless of geography suggesting a need for improved treatments. Our results suggest that the combination of TEM + PAZ + FOLFOX has clinical potential for colorectal cancer patient.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Retrospective data, Journal: Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer. (Pubmed Central) - Mar 5, 2020
Our results suggest that the combination of TEM + PAZ + FOLFOX has clinical potential for colorectal cancer patient. Addition of anti-EGFR in left sided K-RAS wild-type mCRC regarding PFS was beneficial, however there was no difference in terms of OS.
- | Trial completion date, Trial primary completion date, Metastases: Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer (clinicaltrials.gov) - Mar 5, 2020
P4, N=36, Recruiting, Sponsor: University of Chicago
Addition of anti-EGFR in left sided K-RAS wild-type mCRC regarding PFS was beneficial, however there was no difference in terms of OS. Trial completion date: Jan 2019 --> Mar 2026 | Trial primary completion date: Jan 2019 --> Mar 2023
- | Rubraca (rucaparib) / Pharma& Schweiz, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, BRCA Biomarker, PARP Biomarker, Metastases: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (clinicaltrials.gov) - Mar 5, 2020
P2, N=110, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
Trial completion date: Jan 2019 --> Mar 2026 | Trial primary completion date: Jan 2019 --> Mar 2023 Recruiting --> Active, not recruiting
- || Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Trial completion date, Trial primary completion date: Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 4, 2020
P2, N=100, Active, not recruiting, Sponsor: University of California, San Diego
Recruiting --> Active, not recruiting Trial completion date: Jan 2020 --> Jan 2026 | Trial primary completion date: Jan 2020 --> Jan 2024
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (clinicaltrials.gov) - Mar 3, 2020
P2, N=66, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial completion date: Jan 2020 --> Jan 2026 | Trial primary completion date: Jan 2020 --> Jan 2024 Trial completion date: Feb 2020 --> Sep 2020 | Trial primary completion date: Feb 2020 --> Sep 2020
- | Trial completion date, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 3, 2020
P2, N=44, Active, not recruiting, Sponsor: University of Florida
Trial completion date: Feb 2020 --> Sep 2020 | Trial primary completion date: Feb 2020 --> Sep 2020 Trial completion date: Jan 2020 --> Dec 2020
- || veliparib (ABT-888) / AbbVie
Trial completion date, Trial primary completion date, Combination therapy, Metastases: ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 3, 2020
P1/2, N=64, Active, not recruiting, Sponsor: Georgetown University
Trial completion date: Jan 2020 --> Dec 2020 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- | leucovorin calcium / Generic mfg.
Trial initiation date: Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium (clinicaltrials.gov) - Mar 3, 2020
P2, N=80, Not yet recruiting, Sponsor: Phoenix Children's Hospital
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Initiation date: Dec 2019 --> May 2020
- | leucovorin calcium / Generic mfg.
Trial initiation date: Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) - Mar 3, 2020
P2, N=80, Not yet recruiting, Sponsor: Phoenix Children's Hospital
Initiation date: Dec 2019 --> May 2020 Initiation date: Dec 2019 --> May 2020
- || Graspa (eryaspase) / PHAXIAM Therap
New P1 trial: Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Mar 3, 2020
P1, N=18, Not yet recruiting, Sponsor: Georgetown University
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
[VIRTUAL] METHOTREXATE BLOCKS PROLIFERATION NOT INFLAMMATION TO MODULATE IMMUNITY ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_791;
Folinic acid could restore T cell proliferation, but did not fully rescue cell death. Our data are fully consistent with the in vivo effects of MTX in PLWH suggesting that the major effect of MTX on immune function is an inhibition of cellular proliferation.
- | Journal: New progress in the treatment of locally advance pancreatic cancer (Pubmed Central) - Mar 2, 2020
The introduction of chemotherapy with calcium leucovorin, fluorouracil, irinotecan hydrochloride and oxaliplatin (FOLFIRINOX) and gemcitabine-nab (nanoparticle albumin-bound)-paclitaxel (gem-nab) had very important implications for the management of patients with LAPC. After 4 to 6 months of induction chemotherapy, a large proportion of them have stable disease or even tumor regression, allowing to rescue those who initially were not candidates for surgery, with 30-35 months overall survival after surgery.
- | Hepacid (pegargiminase) / Polaris Pharma
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 2, 2020
P1/2, N=141, Terminated, Sponsor: Polaris Group
After 4 to 6 months of induction chemotherapy, a large proportion of them have stable disease or even tumor regression, allowing to rescue those who initially were not candidates for surgery, with 30-35 months overall survival after surgery. N=225 --> 141 | Trial completion date: Oct 2020 --> Feb 2020 | Recruiting --> Terminated | Trial primary completion date: Aug 2020 --> Feb 2020
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
Clinical, Journal: Simplified/Same Day(s)-GOLF as First-line Treatment of Metastatic Carcinoma of Unknown Primary (CUP), Suggestive of Pancreatobiliary Tumors. (Pubmed Central) - Mar 1, 2020
Grade 3-4 toxicities included neutropenia, febrile neutropenia, thrombocytopenia, nausea, diarrhea, mucositis and oxaliplatin-induced neuropathy. Simplified Gemcitabine, Oxaliplatin, Leucovorin and 5-Fluorouracil regimen appears to be feasible with promising activity for Carcinoma of unknown primary and deserves to be evaluated in future trials.
- || leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., Nexavar (sorafenib) / Bayer, Amgen
Biomarker, Clinical, P2 data, Journal: A Phase II and Biomarker Study of Sorafenib Combined with FOLFOX in Patients with Advanced Hepatocellular Carcinoma (HCC). (Pubmed Central) - Feb 29, 2020
Thus, this regimen may be effective in select patients with adequate liver reserve. Biomarker evaluations suggested a correlation between TTP and angiogenic biomarkers and circulating Tregs.
- | leucovorin calcium / Generic mfg.
Journal: Toxoplasma gondii-Induced Brachial Plexus Neuropathy after Allogeneic Hematopoietic Stem Cell Transplantation. (Pubmed Central) - Feb 28, 2020
The diagnosis was made based on the clinical presentation, magnetic resonance imaging of the brachial plexus and positive T. gondii polymerase chain reaction (PCR) in cerebrospinal fluid. The patient was treated with pyrimethamine, sulfadiazine and levofolinic acid during six weeks, with a positive outcome.
- || Biomarker, Clinical, P2 data, Journal: Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study. (Pubmed Central) - Feb 28, 2020
P2
The patient was treated with pyrimethamine, sulfadiazine and levofolinic acid during six weeks, with a positive outcome. The NIFE trial evaluates the potential of a nanoliposomal-irinotecan/5-FU/leucovorin combination in the first line therapy of advanced BTCs and additionally offers a unique chance for translational research.
- ||| locnartecan (PEN-866) - Tarveda Therap, National Cancer Institute / Bethesda
Enrollment change: PEN-866 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Feb 28, 2020
P1/2, N=260, Recruiting, Sponsor: Tarveda Therapeutics
The NIFE trial evaluates the potential of a nanoliposomal-irinotecan/5-FU/leucovorin combination in the first line therapy of advanced BTCs and additionally offers a unique chance for translational research. N=150 --> 260
- | Trial completion date, Trial primary completion date: PENCOLA: Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime (clinicaltrials.gov) - Feb 27, 2020
P=N/A, N=30, Recruiting, Sponsor: Lund University Hospital
N=150 --> 260 Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
- | New P3 trial, Surgery: JCOG1801: Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer (clinicaltrials.gov) - Feb 27, 2020
P3, N=110, Recruiting, Sponsor: National Cancer Center Hospital East
- [VIRTUAL] A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab. (Poster Board 413) - Feb 27, 2020 - Abstract #ASCO2020ASCO_803;
P1
The trial opened to enrollment in Dec 2019 (NCT04164069) and is accepting patients. Research Funding: Pelotonia IDEA grant
- [VIRTUAL] HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment. (Poster Board 276) - Feb 27, 2020 - Abstract #ASCO2020ASCO_554;
A total of 40 cases are planned for registration from 18 institutions in Japan within 2.5 years. Research Funding: None
- [VIRTUAL] Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC). (Poster Board 275) - Feb 27, 2020 - Abstract #ASCO2020ASCO_553;
P2
As of January 2020, this study is recruiting pts at 74 centers. Research Funding: Astellas Pharma, Inc.
- fluorouracil / Generic mfg., Graspa (eryaspase) / ERYtech, irinotecan / Generic mfg.
[VIRTUAL] TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). (Poster Board 274) - Feb 27, 2020 - Abstract #ASCO2020ASCO_552;
P2, P3
IDMC last reviewed the trial in October 2019 and suggested the trial continue as planned. Research Funding: Erytech